Cagrilintide for weight loss: what the scale videos won't tell you

What's this video probably claiming?

Scale videos are a specific genre on weight loss TikTok, and they follow a predictable script. The creator steps on a scale, the number drops, and the hashtag does the real talking. Here, that hashtag is #cagrilintide, which tells us this is almost certainly a progress video documenting weight loss attributed to cagrilintide, either alone or more likely in combination with semaglutide as the dual agent CagriSema. The implicit claim is straightforward: this drug is working, and the scale proves it. Depending on the video content, there may also be secondary claims about how fast the weight came off, the dose being used, or comparisons to GLP-1 drugs like Ozempic. These videos tend to compress weeks of data into a single triumphant moment, which is exactly where the science starts getting blurry.

What does the science actually show?

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It mimics amylin, a hormone co-secreted with insulin that slows gastric emptying and reduces appetite through central pathways distinct from GLP-1. In a 2023 phase 2 trial published in The Lancet (Enebo et al.), participants receiving 2.4 mg cagrilintide weekly lost approximately 10.8% of body weight over 26 weeks. The real data interest, though, is in CagriSema, the fixed-ratio combination with semaglutide 2.4 mg. The SCALE-NEXT phase 3 trial data presented at ENDO 2024 showed mean weight loss of around 22.7% over 68 weeks at the highest dose combination. Those are meaningful numbers, but they come from controlled trials with specific populations, medical monitoring, and titration schedules that a TikTok scale video cannot replicate or validate.

Where does the social media noise diverge from clinical reality?

The gap between a 5,000-view scale video and a clinical trial is significant. First, cagrilintide is not approved by the FDA as a standalone or combination drug for weight loss as of mid-2025. CagriSema is still in phase 3 development. What circulates online is either compounded cagrilintide from unregulated compounding pharmacies or gray-market peptide sources, neither of which has the same manufacturing controls, purity verification, or dosing precision as trial-grade product. Second, scale videos by design strip out confounders: caloric intake, other medications, water retention changes, and baseline starting weight. A dramatic drop in week two is often glycogen depletion and fluid loss, not fat mass reduction. Third, the nausea and injection-site reaction profile of cagrilintide is non-trivial. The Enebo trial reported nausea in roughly 40% of participants and injection-site reactions at higher rates than semaglutide alone.

What should you actually know?

If you are watching scale videos and considering cagrilintide, here is what deserves your attention. The mechanism is genuinely interesting and biologically distinct from GLP-1 agonism, which is why researchers are pursuing the combination. Amylin receptor activation affects the area postrema and the hypothalamus differently than GLP-1 receptor activation, and additive satiety signaling is a real pharmacological concept supported by preclinical and early clinical data. But mechanism is not approval, and anecdote is not evidence. The individuals showing scale drops may be responding to semaglutide alone, to caloric restriction, or to a combination effect that has not been separated in their personal context. Until CagriSema clears FDA review, any cagrilintide a person outside a clinical trial is using comes from sources without regulatory oversight. That is a real risk, not a formality.